title: Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by oridonin nanosuspension.
abstract: The mechanism for anti-tumor activity of oridonin (ORI) nanosuspension, prepared by the high pressure homogenization method, was studied using MCF-7 human breast carcinoma cells in vitro. MTT assay, observation of morphologic changes, flow cytometric analysis, and western blot analysis indicated that ORI nanosuspension could significantly intensify the in vitro anti-tumor activity to MCF-7 cells, as compared with ORI solution. Furthermore, ORI nanosuspension induced G₂/M stage proliferation arrest and apoptosis in MCF-7 cells depending on its concentration. In addition, western blot analysis indicated that the pro-caspase-3 protein was not cleaved into the activated form and the expression of anti-apoptotic Bcl-2 protein decreased, on the contrary, the expression of pro-apoptotic Bax protein increased in a dose-dependent manner in ORI nanosuspension-treated cells. These observations indicated that the anti-tumor activity of ORI nanosuspension was intensified by cell-cycle arrest and apoptosis induction.
authors.affiliation: Department of Pharmaceutics, College of Pharmacy, Shandong University, Shandong Province, PR China.
authors.forename: Fei-Fei
authors.initials: FF
authors.lastname: Feng
authors.forename: Dian-Rui
authors.initials: DR
authors.lastname: Zhang
authors.forename: Ke-Li
authors.initials: KL
authors.lastname: Tian
authors.forename: Hai-Yan
authors.initials: HY
authors.lastname: Lou
authors.forename: Xiao-Li
authors.initials: XL
authors.lastname: Qi
authors.forename: Yan-Cai
authors.initials: YC
authors.lastname: Wang
authors.forename: Cun-Xian
authors.initials: CX
authors.lastname: Duan
authors.forename: Le-Jiao
authors.initials: LJ
authors.lastname: Jia
authors.forename: Fei-Hu
authors.initials: FH
authors.lastname: Wang
authors.forename: Yue
authors.initials: Y
authors.lastname: Liu
authors.forename: Qiang
authors.initials: Q
authors.lastname: Zhang
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D053148:Caspase 3 / Q000235:genetics / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor; D045786:Diterpenes, Kaurane / Q000008:administration & dosage* / Q000737:chemistry; D004305:Dose-Response Relationship, Drug; D005260:Female; D016195:G2 Phase / Q000187:drug effects; D006801:Humans; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism; D013535:Suspensions / Q000008:administration & dosage / Q000737:chemistry; D051028:bcl-2-Associated X Protein / Q000235:genetics / Q000378:metabolism
chemical_list: D045786:Diterpenes, Kaurane; D019253:Proto-Oncogene Proteins c-bcl-2; D013535:Suspensions; D051028:bcl-2-Associated X Protein; C011959:oridonin; D053148:Caspase 3